Organic Active Ingredients TRIZ Cases

Nonpeptide inhibitors replace peptides to resolve permeability and toxicity trade-offs.

Imidazopyridine derivatives induce terminal differentiation in acute myeloid leukemia cells.

Cerdulatinib targets SYK and JAK pathways to overcome resistance in FGFR3-positive and negative multiple myeloma cases.

A hydrogel composition for oral wounds uses polysaccharides, polyols, and essential oils to deliver therapeutic benefits.

Dual-action benzomorphan analogs reduce opioid-induced constipation by targeting mu, delta, kappa receptors while blocking ORL-1.

Topical macrocyclic lactones inhibit viral multiplication at infection sites, preventing relapses and scarring from physical lesion removal.

Phospholipids prevent reagglomeration in nanonized fenofibrate suspensions, maintaining crystalline stability while enhancing dissolution speed.

Segmented beads with semi-permeable coating form viscous gel to prevent active ingredient extraction while maintaining pharmacokinetic release.

M1-selective amide ligands improve cognition while avoiding peripheral cholinergic side effects like nausea.

Evans Blue conjugates reversibly bind serum albumin to extend blood circulation half-life, avoiding renal clearance while maintaining therapeutic efficacy.

Terminal hydroxyl-modified PEG nanocarriers resist pre-existing anti-PEG antibody binding, reducing complement activation and rapid clearance in human blood.

Leukocyte-redirecting bispecific antibodies target effector T cells to induce cytotoxicity against tumor-associated antigens.

Selective binding extracts fibrinogen before lysis, preventing clot formation and preserving growth factor availability.

Anti-PCSK9 antibodies replace invasive lipoprotein apheresis, reducing treatment frequency and improving patient quality of life.

A compound activates HSF1 and NRF2 pathways to promote chaperone expression.

Direct linkage of the peptidic group to the bulky drug moiety eliminates steric hindrance, restoring cytotoxicity while maintaining conjugate stability.

Novel substituted dihydroisoquinolinone compounds inhibit EZH2 activity to treat abnormal cell growth.

Ibuprofen soft gelatin capsules use specific polymer ratios to enhance drug solubilization in gastric fluid for faster onset.

A portable apparatus delivers microparticles of adrenaline directly to the lungs using a positive pressure gas flow.

Segmented chemical structures with varied core rings expand compound diversity while maintaining reliable P53 pathway activation for treating tumors.

Pyridinyl and fused pyridinyl triazolone derivatives act as selective Bruton's tyrosine kinase inhibitors.

Substituted chroman-thiazoles inhibit the sodium-calcium exchanger subtype 1 to stabilize intracellular calcium levels and reduce arrhythmic mortality.

Direct oxidation of six-membered ring heteroatoms creates aldehyde methylene groups without olefinic intermediates or osmium reagents.

PARP1 and DNA ligase IIIα inhibitors block the ALT NHEJ pathway to treat therapy-resistant breast and pancreatic cancers.

Site-directed mutagenesis of AAV9 capsids reduces airway epithelium transduction while maintaining high efficiency in liver and heart tissue.

PDGFRα inhibitors drive OPC differentiation for myelin restoration while maintaining favorable brain-to-plasma ratios.

Algal EPA compositions preserve phospholipids and free fatty acids to increase bioavailability while eliminating DHA variability found in fish oil sources.

Sophorolipids replace synthetic coccidiostats, reducing costs while treating Clostridium diseases.

Tetra-acylated neisserial LPS reduces toxic side effects while maintaining strong TLR4 activation and cytokine production.

Extruded polymer film embeds neuro-regenerative agents to sustain axonal regeneration while avoiding high concentration side effects.

Jasmine extract and lactone suppress sympathetic nerves to expand blood vessels, resolving individual sensitivity variations in circulation improvement.

A spiro-beta-carboline compound acts as a TSPO antagonist to suppress pain thresholds in fibromyalgia treatment.

Combining G-CSF with TLR4 antagonists mitigates inflammation while enhancing hepatocyte proliferation.

Dual antisense oligonucleotides target internal exon sequences to block splicing enhancers and drive exon exclusion.

Subgenomic replicon systems evaluate nucleoside inhibitor efficacy against HCV replication machinery without complex animal models.

A ternary lipid association of beta-sitosterol, isocetyl stearoyl stearate, and glyceryl tri-2-ethylhexanoate optimizes intercorneocyte spaces.

A bispecific antibody binds ErbB-2 and ErbB-3 receptors to inhibit dimerization.

Novel sulfonyl amidine compounds inhibit indoleamine-2,3-dioxygenase enzyme activity to enhance immune response against tumors.

Tacrolimus suppresses cell-mediated immunity to prevent fetal rejection, resolving risks to mother and fetus associated with conventional steroid therapies.

Topical dantrolene acts as a ryanodine receptor antagonist to improve microcirculation and reduce inflammation in deep dermal wounds.

Embryonic progenitor cell lines expand over 40 passages to produce diverse cartilage types without hypertrophic markers.

Segmented azonafide compounds use peptide linkers for targeted delivery, reducing systemic toxicity while maintaining tumor growth inhibition.

A simplified dasatinib synthesis method uses Boc-protected thiazole intermediates to achieve high purity.

Genetic engineering of dendritic cells extends the immune stimulatory window by maintaining IL-12 secretion and suppressing suppressive molecules.

Ketamine antagonizes NMDA receptors to reduce excitotoxicity, slowing muscle loss and extending life expectancy beyond conventional riluzole efficacy.

Combining glycolysis inhibitors with histone deacetylase inhibitors suppresses tumor growth.